WO2015022545A3 - Microparticules de cellules souches et miarn - Google Patents

Microparticules de cellules souches et miarn Download PDF

Info

Publication number
WO2015022545A3
WO2015022545A3 PCT/GB2014/052509 GB2014052509W WO2015022545A3 WO 2015022545 A3 WO2015022545 A3 WO 2015022545A3 GB 2014052509 W GB2014052509 W GB 2014052509W WO 2015022545 A3 WO2015022545 A3 WO 2015022545A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cell
microparticles
mirna
cell line
cell microparticles
Prior art date
Application number
PCT/GB2014/052509
Other languages
English (en)
Other versions
WO2015022545A2 (fr
Inventor
Caroline Hicks
John Sinden
Lara Stevanato
Randolph Corteling
Original Assignee
Reneuron Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1314573.5A external-priority patent/GB201314573D0/en
Priority claimed from GB201317887A external-priority patent/GB201317887D0/en
Priority to US14/912,060 priority Critical patent/US20160193252A1/en
Priority to JP2016533960A priority patent/JP6491661B2/ja
Priority to KR1020167006268A priority patent/KR20160035087A/ko
Priority to EP14755411.7A priority patent/EP3033418B1/fr
Priority to CA2920948A priority patent/CA2920948A1/fr
Priority to BR112016003053A priority patent/BR112016003053A2/pt
Application filed by Reneuron Limited filed Critical Reneuron Limited
Priority to AU2014307750A priority patent/AU2014307750A1/en
Priority to CN201480056305.2A priority patent/CN105658789B/zh
Priority to JP2016520587A priority patent/JP2016534036A/ja
Priority to US15/027,424 priority patent/US10406182B2/en
Priority to EP14790257.1A priority patent/EP3055411A1/fr
Priority to PCT/GB2014/053044 priority patent/WO2015052526A1/fr
Publication of WO2015022545A2 publication Critical patent/WO2015022545A2/fr
Publication of WO2015022545A3 publication Critical patent/WO2015022545A3/fr
Priority to US16/521,298 priority patent/US20190381105A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/088—Coculture with; Conditioned medium produced by cells of the nervous system neural stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)

Abstract

Cette invention concerne des microparticules de cellules souches et des miARN isolés à partir de ces microparticules, leur utilisation et leur production, en particulier des microparticules de cellules souches neurales, et leur utilisation en thérapie pour le traitement d'une maladie ou d'un état impliquant la migration cellulaire indésirable ou non souhaitée. La microparticule de cellules souches est typiquement un exosome ou une microvésicule et peut être dérivée d'une lignée de cellules souches neurales. La lignée de cellules souches neurales peut être une lignée de cellules souches conditionnellement immortalisée telle que CTX0E03 (déposée à l'ECACC avec le numéro d'ordre 04091601).
PCT/GB2014/052509 2013-08-14 2014-08-14 Microparticules de cellules souches et miarn WO2015022545A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201480056305.2A CN105658789B (zh) 2013-08-14 2014-08-14 干细胞微粒和miRNA
JP2016533960A JP6491661B2 (ja) 2013-08-14 2014-08-14 幹細胞微粒子及びｍｉＲＮＡ
AU2014307750A AU2014307750A1 (en) 2013-08-14 2014-08-14 Stem cell microparticles and miRNA
KR1020167006268A KR20160035087A (ko) 2013-08-14 2014-08-14 줄기 세포 마이크로입자 및 miRNA
EP14755411.7A EP3033418B1 (fr) 2013-08-14 2014-08-14 Microparticules de cellules souches et miarn
CA2920948A CA2920948A1 (fr) 2013-08-14 2014-08-14 Microparticules de cellules souches et miarn
BR112016003053A BR112016003053A2 (pt) 2013-08-14 2014-08-14 micropartículas de células tronco e mirna
US14/912,060 US20160193252A1 (en) 2013-08-14 2014-08-14 STEM CELL MICROPARTICLES AND miRNA
JP2016520587A JP2016534036A (ja) 2013-10-09 2014-10-09 幹細胞微粒子及びｍｉＲＮＡ
PCT/GB2014/053044 WO2015052526A1 (fr) 2013-10-09 2014-10-09 Microparticules et micro-arn de cellules souches
EP14790257.1A EP3055411A1 (fr) 2013-10-09 2014-10-09 Microparticules et micro-arn de cellules souches
US15/027,424 US10406182B2 (en) 2013-10-09 2014-10-09 Stem cell microparticles and miRNA
US16/521,298 US20190381105A1 (en) 2013-10-09 2019-07-24 STEM CELL MICROPARTICLES AND miRNA

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1314573.5A GB201314573D0 (en) 2013-08-14 2013-08-14 Product
GB1314573.5 2013-08-14
GB201317887A GB201317887D0 (en) 2013-10-09 2013-10-09 Product
GB1317887.6 2013-10-09

Publications (2)

Publication Number Publication Date
WO2015022545A2 WO2015022545A2 (fr) 2015-02-19
WO2015022545A3 true WO2015022545A3 (fr) 2015-04-16

Family

ID=51398642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/052509 WO2015022545A2 (fr) 2013-08-14 2014-08-14 Microparticules de cellules souches et miarn

Country Status (9)

Country Link
US (1) US20160193252A1 (fr)
EP (1) EP3033418B1 (fr)
JP (1) JP6491661B2 (fr)
KR (1) KR20160035087A (fr)
CN (1) CN105658789B (fr)
AU (1) AU2014307750A1 (fr)
BR (1) BR112016003053A2 (fr)
CA (1) CA2920948A1 (fr)
WO (1) WO2015022545A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286463B2 (en) 2012-03-08 2022-03-29 Advanced ReGen Medical Technologies, LLC Reprogramming of aged adult stem cells
US20150164955A1 (en) * 2012-07-19 2015-06-18 Reneuron Limited Stem cell microparticles
WO2014197421A1 (fr) 2013-06-05 2014-12-11 Biotime, Inc. Compositions et procédés pour la régénération de tissus induite chez des espèces mammaliennes
GB201317887D0 (en) * 2013-10-09 2013-11-20 Reneuron Ltd Product
JP6353073B2 (ja) 2013-12-20 2018-07-04 アドヴァンスド リジェン メディカル テクノロジーズ，エルエルシー 細胞回復のための組成物並びにその作製及び使用方法
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) * 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
JP6841040B2 (ja) 2015-12-10 2021-03-10 東レ株式会社 癌の治療及び／又は予防用医薬組成物
JP6999575B2 (ja) 2016-04-29 2022-01-18 アドヴァンスド リジェン メディカル テクノロジーズ，エルエルシー マイクロｒｎａ組成物並びにその作製及び使用方法
US12016884B2 (en) 2016-08-30 2024-06-25 University Of South Florida Adipose derived stem cell exosomes and uses thereof
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
US11345957B2 (en) 2017-07-18 2022-05-31 Exosome Diagnostics, Inc. Methods of treating glioblastoma in a subject informed by exosomal RNA signatures
EP4218775A1 (fr) * 2017-08-04 2023-08-02 Cedars-Sinai Medical Center Cellules dérivées de la cardiosphère et leurs vésicules extracellulaires pour le traitement et la prévention du cancer
GB201716408D0 (en) * 2017-10-06 2017-11-22 Reneuron Ltd Stem cell microparticles for cancer therapy
WO2019126068A1 (fr) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Vésicules extracellulaires modifiées pour une administration tissulaire améliorée
EP3775908A1 (fr) * 2018-04-13 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prédiction de l'évolution et du traitement de patients souffrant d'un cancer de la prostate ou d'un cancer du sein
CA3117218A1 (fr) * 2018-10-25 2020-04-30 Quadrant Biosciences Inc. Procedes et apprentissage automatique pour diagnostic de maladie
CN109762903B (zh) * 2019-01-31 2022-02-01 山东大学齐鲁医院 miR-1246和/或TERF2IP在诊治胶质瘤中的应用
US20240024220A1 (en) * 2019-05-11 2024-01-25 Youngsuk Yi Neurotoxin compositions and methods
EP4013869A1 (fr) * 2019-08-12 2022-06-22 InteRNA Technologies B.V. Nouveaux traitements impliquant le miarn-193a
CN110885881A (zh) * 2019-11-14 2020-03-17 南通大学 去神经支配海马外泌体研究海马神经再生微环境的方法
CN111440800B (zh) * 2020-04-20 2023-04-28 南通大学附属医院 靶向Galectin-3基因的miRNA-128-3p及其抗胰腺癌的用途
CN114763523A (zh) * 2020-12-30 2022-07-19 西比曼生物科技（上海）有限公司 一种提高人体细胞衍生的细胞膜外囊泡中特定miRNA含量的方法
KR20220109589A (ko) * 2021-01-29 2022-08-05 부산대학교 산학협력단 miR-486-5p를 유효성분으로 함유하는 간섬유증 예방 또는 치료용 약학적 조성물
CN113151477B (zh) * 2021-05-08 2022-04-15 武汉大学中南医院 用于检测肠癌的miRNA标记物及其应用
CN115737557B (zh) * 2022-11-18 2024-04-09 黑龙江中医药大学 一种miR-55制剂及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100081003A (ko) * 2009-01-05 2010-07-14 서울대학교산학협력단 인간 신경 줄기세포 유래 면역조절 활성을 갖는 미세소낭 및 이를 유효성분으로 하는 면역조절제
WO2013150303A1 (fr) * 2012-04-03 2013-10-10 Reneuron Limited Microparicules de cellules souches
WO2014013258A1 (fr) * 2012-07-19 2014-01-23 Reneuron Limited Microparticules de cellules souches

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232430A1 (en) * 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
EP2211875B1 (fr) * 2007-10-29 2013-05-29 Fresenius Medical Care Deutschland GmbH Utilisation de microvésicules (mv) dérivées de cellules-souches pour la préparation d'un médicament destiné la régénération endothéliale/épithéliale de tissus ou d'organes endommagés ou lésés, et procédés in vitro et in vivo associés
PT2254586E (pt) * 2008-02-22 2015-05-18 Agency Science Tech & Res Partículas de células estaminais mesenquimais
CN101890050B (zh) * 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
GB201302468D0 (en) * 2013-02-12 2013-03-27 Reneuron Ltd Stem cell product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100081003A (ko) * 2009-01-05 2010-07-14 서울대학교산학협력단 인간 신경 줄기세포 유래 면역조절 활성을 갖는 미세소낭 및 이를 유효성분으로 하는 면역조절제
WO2013150303A1 (fr) * 2012-04-03 2013-10-10 Reneuron Limited Microparicules de cellules souches
WO2014013258A1 (fr) * 2012-07-19 2014-01-23 Reneuron Limited Microparticules de cellules souches

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHENJIE YANG ET AL: "Immunosuppressive Exosomes: A New Approach for Treating Arthritis", INTERNATIONAL JOURNAL OF RHEUMATOLOGY, vol. 176, no. 12, 1 January 2012 (2012-01-01), pages 7385 - 8, XP055155835, ISSN: 1687-9260, DOI: 10.1038/labinvest.2010.152 *
DUKJIN KANG ET AL: "Proteomic Analysis of Exosomes from Human Neural Stem Cells by Flow Field-Flow Fractionation and Nanoflow Liquid Chromatography-Tandem Mass Spectrometry", JOURNAL OF PROTEOME RESEARCH, vol. 7, no. 8, 1 August 2008 (2008-08-01), pages 3475 - 3480, XP055066064, ISSN: 1535-3893, DOI: 10.1021/pr800225z *
E. VAN DER POL ET AL: "Classification, Functions, and Clinical Relevance of Extracellular Vesicles", PHARMACOLOGICAL REVIEWS, vol. 64, no. 3, 1 July 2012 (2012-07-01), pages 676 - 705, XP055155968, ISSN: 0031-6997, DOI: 10.1124/pr.112.005983 *
INDIRA VISHNUBHATLA ET AL: "The Development of Stem Cell-derived Exosomes as a Cell-free Regenerative Medicine", JOURNAL OF CIRCULATING BIOMARKERS, vol. 3, no. 2, 30 April 2014 (2014-04-30), pages 1 - 14, XP055155696, DOI: 10.5772/58597 *

Also Published As

Publication number Publication date
BR112016003053A2 (pt) 2017-09-12
CN105658789A (zh) 2016-06-08
US20160193252A1 (en) 2016-07-07
WO2015022545A2 (fr) 2015-02-19
JP6491661B2 (ja) 2019-03-27
JP2016534103A (ja) 2016-11-04
CA2920948A1 (fr) 2015-02-19
KR20160035087A (ko) 2016-03-30
EP3033418B1 (fr) 2019-12-11
AU2014307750A1 (en) 2016-02-25
EP3033418A2 (fr) 2016-06-22
CN105658789B (zh) 2020-07-14

Similar Documents

Publication Publication Date Title
WO2015022545A3 (fr) Microparticules de cellules souches et miarn
WO2017030823A3 (fr) Anticorps anti-tigit
WO2016011306A3 (fr) Modifications de terminal de polynucléotides
EP3668497A4 (fr) Procédés et compositions de traitement de maladies associées au cancer, à une inflammation ou à une réponse immunitaire
WO2015073587A3 (fr) Complexes membrane synthétique- récepteur
WO2015143046A3 (fr) Procédés et compositions pour la régulation sélective de l'expression de protéine à doigt à zinc
WO2014191359A9 (fr) Aptamères et utilisation d'aptamères dans le diagnostic et le traitement du cancer
EP3302541A4 (fr) Procédés et dispositifs pour la production et l'administration de facteurs bénéfiques à partir de cellules souches
WO2014047486A3 (fr) Microcapsules à séchage par pulvérisation
WO2012114204A3 (fr) Procédés de traitement d'une dysfonction mitochondriale
EP3305364B8 (fr) Défibrillateur cardioverteur vestimentaire (wcd) ayant une fonction d'économie d'énergie
IL285258A (en) Retinal ganglion cells and their progenitor cells
WO2016077639A3 (fr) Thérapies nanovésiculaires
WO2015106273A3 (fr) Méthodes et dosages concernant la chorée de huntington et la maladie de parkinson
EP3325608A4 (fr) Procédés et micro-organismes de production de 1,3-butanediol
EP3178091A4 (fr) Réseaux métalliques conducteurs comprenant des nanofils métalliques et des nanoparticules métalliques, et procédés de fabrication
WO2014151456A3 (fr) Traitement de maladies inflammatoires
EP3283157A4 (fr) Endoprothèses vaginales, dilatateurs vaginaux et leurs procédés de fabrication
WO2015120372A3 (fr) Compositions et méthodes d'inhibition de ezh2 pour traiter des maladies cardiovasculaires
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
EP3294931A4 (fr) Composition de plomb déposée par électrolyse, procédés pour sa production, et utilisations
WO2015106043A3 (fr) Nouvelle technologie adcc fondée sur la biologie de synthèse
IL262747A (en) Anti-kv1.3 antibodies, methods for their production and use
EP3229793A4 (fr) Compositions et méthodes se rapportant au traitement de cancers, de maladies autoimmunes et de maladies neurodégénératives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14755411

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2920948

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016533960

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14912060

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016003053

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014307750

Country of ref document: AU

Date of ref document: 20140814

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167006268

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2014755411

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112016003053

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160212